COCP - コクリスタル・ファ―マ (Cocrystal Pharma Inc.) コクリスタル・ファ―マ



symbol COCP
会社名 Cocrystal Pharma Inc (コクリスタル・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Cocrystal Pharma Inc. is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.   コクリスタル・ファ―マは米国の医薬品企業。主にヒトのウィルス性疾患の治療薬の開発に従事する。ウィルスの複製機能を阻害する抗ウィルス治療薬で、RNAポリメラ―ゼ酵素、ヘリカ―ゼ酵素、C型肝炎のNS5Aたんぱく質、インフルエンザウィルスやノロウィルスのRNAポリメラ―ゼを含む。同社は薬物レベルでの酵素相互作用に焦点を当てる。本社はジョ―ジア州タッカ―。   Cocrystal Pharma Inc develops novel medicines for the treatment of human viral diseases. It focuses on the development and commercialization of broad-spectrum antiviral drug candidates that transforms the treatment and prophylaxis of diseases in humans.
本社所在地 1860 Montreal Road Tucker GA 30084 USA
代表者氏名 Raymond F. Schinazi レイモンドF.シナジー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 425-398-7178
設立年月日 39052
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 10人
EBITDA EBITDA(百万ドル) -8.06300
終値(lastsale) 2.725
時価総額(marketcap) 81540382.1
時価総額 時価総額(百万ドル) 81.98923
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 75.14823
当期純利益 当期純利益(百万ドル) 0.04100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cocrystal Pharma Inc revenues was not reported. Net loss decreased 18% to $2.9M. Lower net loss reflects Research and development decrease of 40% to $2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.15 to -$0.11.



   Midday Gainers / Losers  2018-12-14
Gainers: Alliqua BioMedical (NASDAQ: ALQA ) +40% . Belmond (NYSE: BEL ) +40% . Civitas Solutions (NYSE: CIVI ) +20% . XPO Logistics (NYSEMKT: XPO ) +14% . Wheaton Precious Metals (NYSE: WPM ) +14% . China Internet Nationwide Financial (NASDAQ: CIFS ) +14% . Fusion Connect (NASD…

 関連キーワード  (医薬品 米国株 コクリスタル・ファ―マ COCP Cocrystal Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)